Zydus Lifesciences Management
Management criteria checks 3/4
Zydus Lifesciences' CEO is Sharvil Patel, appointed in Apr 2017, has a tenure of 7.75 years. total yearly compensation is ₹300.00M, comprised of 60% salary and 40% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth ₹14.73M. The average tenure of the management team and the board of directors is 5.9 years and 7.5 years respectively.
Key information
Sharvil Patel
Chief executive officer
₹300.0m
Total compensation
CEO salary percentage | 60.0% |
CEO tenure | 7.8yrs |
CEO ownership | 0.001% |
Management average tenure | 5.9yrs |
Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Might Deserve Your Attention Today
Dec 16These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely
Nov 30Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | ₹43b |
Jun 30 2024 | n/a | n/a | ₹42b |
Mar 31 2024 | ₹300m | ₹180m | ₹38b |
Dec 31 2023 | n/a | n/a | ₹30b |
Sep 30 2023 | n/a | n/a | ₹28b |
Jun 30 2023 | n/a | n/a | ₹25b |
Mar 31 2023 | ₹263m | ₹180m | ₹20b |
Dec 31 2022 | n/a | n/a | ₹21b |
Sep 30 2022 | n/a | n/a | ₹20b |
Jun 30 2022 | n/a | n/a | ₹22b |
Mar 31 2022 | ₹200m | ₹180m | ₹22b |
Dec 31 2021 | n/a | n/a | ₹23b |
Sep 30 2021 | n/a | n/a | ₹23b |
Jun 30 2021 | n/a | n/a | ₹23b |
Mar 31 2021 | ₹263m | ₹180m | ₹22b |
Dec 31 2020 | n/a | n/a | ₹18b |
Sep 30 2020 | n/a | n/a | ₹17b |
Jun 30 2020 | n/a | n/a | ₹13b |
Mar 31 2020 | ₹250m | ₹247m | ₹12b |
Dec 31 2019 | n/a | n/a | ₹12b |
Sep 30 2019 | n/a | n/a | ₹14b |
Jun 30 2019 | n/a | n/a | ₹17b |
Mar 31 2019 | ₹250m | ₹248m | ₹18b |
Dec 31 2018 | n/a | n/a | ₹20b |
Sep 30 2018 | n/a | n/a | ₹20b |
Jun 30 2018 | n/a | n/a | ₹21b |
Mar 31 2018 | ₹250m | ₹248m | ₹18b |
Compensation vs Market: Sharvil's total compensation ($USD3.47M) is above average for companies of similar size in the Indian market ($USD1.07M).
Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.
CEO
Sharvil Patel (45 yo)
7.8yrs
Tenure
₹300,000,000
Compensation
Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Executive Director | 7.8yrs | ₹300.00m | 0.0015% ₹ 14.7m | |
COO & Executive Director | 7.5yrs | ₹140.00m | 0.035% ₹ 346.3m | |
President & CEO of America | 1.3yrs | no data | no data | |
Chief Financial Officer | no data | ₹54.31m | no data | |
Head of Investor Relations | no data | no data | no data | |
Company Secretary & Compliance Officer | 5.9yrs | ₹2.09m | no data | |
President of Parenteral Operations | no data | no data | no data |
5.9yrs
Average Tenure
50yo
Average Age
Experienced Management: ZYDUSLIFE's management team is seasoned and experienced (5.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
MD & Executive Director | 27.4yrs | ₹300.00m | 0.0015% ₹ 14.7m | |
COO & Executive Director | 7.5yrs | ₹140.00m | 0.035% ₹ 346.3m | |
Non-Executive Chairman | 29.7yrs | ₹1.20m | 74.98% ₹ 750.4b | |
Independent Director | 8.7yrs | ₹4.00m | no data | |
Non-Executive Non-Independent Director | 27.4yrs | ₹4.00m | 0.0012% ₹ 11.6m | |
Independent Non-Executive Director | 6.1yrs | ₹4.10m | no data | |
Independent Director | 2.2yrs | ₹3.50m | no data | |
Independent Director | 2.2yrs | ₹3.50m | no data | |
Independent Director | less than a year | no data | 0.00044% ₹ 4.4m |
7.5yrs
Average Tenure
56yo
Average Age
Experienced Board: ZYDUSLIFE's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/20 12:28 |
End of Day Share Price | 2025/01/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zydus Lifesciences Limited is covered by 70 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nitin Bhasin | Ambit Capital |
null null | Anand Rathi Shares and Stock Brokers Limited |
Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |